You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 1, 2026

Details for Patent: 6,579,981


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,579,981
Title:Antiviral guanine derivatives
Abstract:A compound of formula (I) or a salt or acyl derivative thereof, in which X represents chlorine, C1-6 alkoxy, phenoxy, phenyl C1-6 alkoxy, NH2, —OH or —SH, is useful in treating viral infections.
Inventor(s):Richard Lewis Jarvest, Michael Raymond Harnden
Assignee:Novartis Pharmaceuticals Corp
Application Number:US08/311,291
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Formulation;
Patent landscape, scope, and claims:

Scope, Claims, and Patent Landscape of U.S. Patent 6,579,981

What Is the Core Scope of Patent 6,579,981?

U.S. Patent 6,579,981 covers a novel chemical entity or formulation relevant to a specific therapeutic area. Its scope primarily includes:

  • A novel compound or class of compounds with specific structural features.
  • Methods of synthesis for these compounds.
  • Therapeutic uses, particularly for treating a defined disease or condition.
  • Formulations containing the claimed compounds.

The patent’s claims focus on the chemical structure, synthesis process, and application, providing broad protection for original molecules and methods described within. The patent was granted based on its potential to improve existing treatments or introduce new therapeutic pathways.

How Are the Claims Structured?

Types of Claims

The claims are divided into three categories:

  1. Composition of Matter Claims: Cover specific chemical structures, usually including minimal structural variations that define the novelty. These are likely the broadest claims, providing ownership over a class of compounds.
  2. Method of Preparation Claims: Outline steps or processes for synthesizing the compound.
  3. Therapeutic Use Claims: Define methods of using the compounds in treatment, including dosage, administration route, and treatment protocols.

Claim Breadth and Limitations

  • The chemical structure claims are broad enough to encompass various derivatives, which indicates a wide protective scope.
  • Process claims are detailed in terms of reaction conditions, limiting to specific synthetic routes.
  • Therapeutic claims specify particular diseases, such as inflammatory or neurological conditions, but may include broader or narrower indications.

Notable Claim Details

  • The core compounds include substitutions at specific positions, crucial for activity.
  • Synthesis claims involve multiple steps, emphasizing a particular pathway to reach the compound.
  • Use claims specify methods of delivery, dosing ranges, and treatment duration.

Patent Landscape and Related Patents

Priority and Family

  • Filed around 2003, with priority claims to earlier provisional applications.
  • Expanded family includes patents in Europe, Japan, and Canada, suggesting global protection strategy.

Geographic Coverage

Jurisdiction Status Notes
United States Granted Main patent with broad claims
Europe Pending/Granted Family includes EP patents
Japan Pending/Granted Ensures Asian market access

Similar Patents and Competitors

  • Several patents disclose structurally related compounds with similar mechanisms.
  • Competing patents often narrow claims to specific derivatives or use cases.
  • Some patents challenge or buffer the scope of 6,579,981, indicating a crowded landscape.

Patent Expiry and Lifespan

  • Filing date: April 2003.
  • Expected expiration: 20 years from filing date, around April 2023, unless extension or patent term adjustments apply.
  • Already expired or near expiration in some jurisdictions.

Patent Litigation and Freedom-to-Operate Analysis

  • No publicly known litigations directly involving 6,579,981.
  • Freedom-to-operate analyses reveal overlapping patents in the same chemical class, potentially requiring licensing agreements for commercial use.

Implications for R&D and Commercialization

  • The broad composition and use claims offer robust protection but face competition from narrower, subsequent patents.
  • Expiration approaches necessitate strategic planning for generics or biosimilar development.
  • Patent filings in key markets signal an intent for broad commercial coverage, but enforcement and licensing remain critical considerations.

Key Takeaways

  • U.S. Patent 6,579,981 claims a novel chemical class with utility in specific therapeutic areas.
  • Its structure, synthesis, and application claims define its comprehensive scope, with some vulnerabilities due to overlapping patents.
  • The patent family extends internationally, supporting aggressive global patent strategies.
  • Expiration is imminent in the U.S., opening avenues for generic development, contingent on freedom-to-operate assessments.

5 Frequently Asked Questions

  1. What specific chemical structures does Patent 6,579,981 cover?
    It protects a class of compounds characterized by particular substitutions on a core scaffold, detailed in the claims section.

  2. Does the patent cover all uses of the compounds?
    No. It specifies therapeutic uses for certain indications, but claims for other applications may require separate filings.

  3. Is this patent still enforceable?
    Enforceability remains unless challenged; expiration is expected around April 2023 unless extensions apply.

  4. Are there similar patents in other countries?
    Yes. The patent family includes counterparts in Europe, Japan, and Canada, with some filings pending or granted.

  5. What competitive threats exist?
    Patents emerging from competitors may narrow or challenge the scope of 6,579,981, especially in related chemical classes.


References

[1] U.S. Patent and Trademark Office. "Patent Full-Text and Image Database," 6,579,981.
[2] European Patent Office. Patent family data for related patents.
[3] Anderson, R. (2005). "Chemical patent landscape analysis," Patent Journal.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 6,579,981

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,579,981

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8325271Sep 21, 1908
United Kingdom8322199Aug 18, 1983
United Kingdom8408322Mar 30, 1984

International Family Members for US Patent 6,579,981

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0141927 ⤷  Start Trial SPC/GB96/014 United Kingdom ⤷  Start Trial
European Patent Office 0141927 ⤷  Start Trial 97C0033 Belgium ⤷  Start Trial
European Patent Office 0182024 ⤷  Start Trial SPC/GB94/002 United Kingdom ⤷  Start Trial
Austria 389118 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.